Analysis and characterization of extrachromosomal circular DNA in prostate cancer: Potential biomarker discovery from urine, plasma, and tumor samples
Authors:
- 12 June 2025
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 628, 217875
Abstract
No abstract availableKeywords
Funding Information
- Taishan Scholar Foundation of Shandong Province (tstp20240526, tstp20221165)
- Qingdao University
- Natural Science Foundation of Shandong Province (2021ZDSYS06, YDZX2021009)
This publication has 42 references indexed in Scilit:
- Extrachromosomal circular DNA-related SPOCK1 contributes to development and enzalutamide resistance of prostate cancer by regulating epithelial mesenchymal transitionHeliyon, 2024
- PSA, an outdated biomarker for prostate cancer: In search of a more specific biomarker, citrate takes the spotlightThe Journal of Steroid Biochemistry and Molecular Biology, 2024
- Extrachromosomal circular DNA (eccDNA): from carcinogenesis to drug resistanceClinical and Experimental Medicine, 2024
- Plasma extrachromosomal circular DNA is a pathophysiological hallmark of short‐term intensive insulin therapy for type 2 diabetesClinical and Translational Medicine, 2023
- Current therapy and drug resistance in metastatic castration-resistant prostate cancerDrug Resistance Updates, 2023
- Extrachromosomal circular DNA: biogenesis, structure, functions and diseasesSignal Transduction and Targeted Therapy, 2022
- Extrachromosomal circular DNA in cancer: history, current knowledge, and methodsTrends in Genetics, 2022
- Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancerLaboratory Investigation, 2017
- A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason ScoreEuropean Urology, 2016
- Random ForestsMachine Learning, 2001